Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors.

Chen YW, Pan HB, Tseng HH, Hung YT, Huang JS, Chou CP.

Int J Mol Sci. 2013 Aug 27;14(9):17536-52. doi: 10.3390/ijms140917536.

2.

Application of 128 slice 4D CT whole liver perfusion imaging in hepatic tumor.

Guo M, Yu Y.

Cell Biochem Biophys. 2014 Sep;70(1):173-8. doi: 10.1007/s12013-014-9877-8.

PMID:
24691926
3.

Evaluation of hepatocellular carcinoma with computed tomography perfusion imaging.

Bayraktutan Ü, Kantarci A, Oğul H, Kizrak Y, Özyiğit Ö, Yüceler Z, Genç B, Özoğul B.

Turk J Med Sci. 2014;44(2):193-6.

PMID:
25536723
4.

Assessment of tumor vascularization with functional computed tomography perfusion imaging in patients with cirrhotic liver disease.

Li JP, Zhao DL, Jiang HJ, Huang YH, Li DQ, Wan Y, Liu XD, Wang JE.

Hepatobiliary Pancreat Dis Int. 2011 Feb;10(1):43-9.

PMID:
21269934
5.

VEGFR-2 expression in HCC, dysplastic and regenerative liver nodules, and correlation with pre-biopsy Dynamic Contrast Enhanced CT.

Thaiss WM, Kaufmann S, Kloth C, Nikolaou K, Bösmüller H, Horger M.

Eur J Radiol. 2016 Nov;85(11):2036-2041. doi: 10.1016/j.ejrad.2016.09.012. Epub 2016 Sep 13.

PMID:
27776657
6.

Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging.

Ippolito D, Capraro C, Casiraghi A, Cestari C, Sironi S.

Eur Radiol. 2012 Apr;22(4):803-11. doi: 10.1007/s00330-011-2307-z. Epub 2011 Nov 16.

PMID:
22086560
7.

Multiphase contrast-enhanced CT imaging in hepatocellular carcinoma correlation with immunohistochemical angiogenic activities.

Kim YI, Chung JW, Park JH, Kang GH, Lee M, Suh KS, Kim KG.

Acad Radiol. 2007 Sep;14(9):1084-91.

PMID:
17707316
8.

Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.

Ippolito D, Sironi S, Pozzi M, Antolini L, Ratti L, Alberzoni C, Leone EB, Meloni F, Valsecchi MG, Fazio F.

Acad Radiol. 2008 Jul;15(7):919-27. doi: 10.1016/j.acra.2008.02.005.

PMID:
18572129
9.

Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, Chakraborti A, Duseja A, Kalra N, Dhiman RK.

Mol Cell Biochem. 2013 Nov;383(1-2):103-12. doi: 10.1007/s11010-013-1759-7. Epub 2013 Aug 4.

PMID:
23912396
10.

Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.

Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T, Okada Y.

J Gastroenterol. 1998 Jun;33(3):376-82.

PMID:
9658317
11.

Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.

Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL.

Radiology. 2005 May;235(2):509-16.

PMID:
15858091
12.

[Hemodynamic study of hepatocellular carcinoma nodules by multi-slice spiral computed tomographic perfusion].

Ma GL, Jiang HJ, Chen M.

Zhonghua Yi Xue Za Zhi. 2013 Apr 16;93(15):1146-9. Chinese.

PMID:
23902883
13.

Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using Volume Perfusion CT with 80 kVp.

Thaiss WM, Haberland U, Kaufmann S, Spira D, Thomas C, Nikolaou K, Horger M, Sauter AW.

Eur Radiol. 2016 Sep;26(9):2929-36. doi: 10.1007/s00330-015-4154-9. Epub 2015 Dec 17.

PMID:
26679179
14.

Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique.

Kaufmann S, Horger T, Oelker A, Kloth C, Nikolaou K, Schulze M, Horger M.

Eur J Radiol. 2015 Jun;84(6):1029-35. doi: 10.1016/j.ejrad.2015.02.020. Epub 2015 Mar 6.

PMID:
25816994
15.

A correlation of computed tomography perfusion and histopathology in tumor edges of hepatocellular carcinoma.

Bai RJ, Li JP, Ren SH, Jiang HJ, Liu XD, Ling ZS, Huang Q, Feng GL.

Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):612-7.

PMID:
25475863
16.
17.

Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.

Hayano K, Lee SH, Yoshida H, Zhu AX, Sahani DV.

Acad Radiol. 2014 May;21(5):654-60. doi: 10.1016/j.acra.2014.01.020.

PMID:
24703479
18.

[Hemodynamic study of primary hepatocellular carcinoma evolved from viral-induced cirrhosis using CT perfusion imaging].

Zhang Q, Zhang XL, Zhang YZ, Cheng GX, Chen ZQ.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Nov;28(11):1986-9. Chinese.

19.

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F.

Oncologist. 2012;17(8):1063-72. doi: 10.1634/theoncologist.2011-0465. Epub 2012 Jun 15.

20.

Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma.

Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, Lisman T.

Platelets. 2015;26(6):577-82. doi: 10.3109/09537104.2014.961415. Epub 2014 Oct 2.

PMID:
25275728

Supplemental Content

Support Center